Myelodysplastic Syndromes
March 2021 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Authors:Morice PM, Leary A, Dolladille C, Chrétien B, Poulain L, González-Martín A, Moore K, O'Reilly EM, Ray-Coquard I, Alexandre J
Institution:Normandie Univ, UNICAEN, INSERM U1086, Interdisciplinary Research Unit for Cancers Prevention and Treatment, Biology and Innovative Therapeutics for Ovarian Cancers Team, Caen, France; UNICANCER, Cancer Center Francois Baclesse, Caen, France. Department of Pharmacology, Pharmacoepidemiology Unit, Caen University Hospital, Caen, France; Normandie Univ, UNICAEN, EA4650, Signalisation, Electrophysiologie et Imagerie des Lesions d'Ischemie-Reperfusion Myocardique, Caen, France; Pharmacovigilance Regional Center, Caen University Hospital, Caen, France. Electronic address: alexandre-j@chu-caen.fr.
Journal:Lancet Haematol. 2021 Feb;8(2):e122-e134. doi: 10.1016/S2352-3026(20)30360-4. Epub 2020 Dec 18.

2:Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(†☆).
Authors:Fenaux P, Haase D, Santini V, Sanz GF, Platzbecker U, Mey U
Institution:Service d'Hematologie Clinique, Groupe Francophone des Myelodysplasies (GFM), Department of Hematology, Hopital St. Louis (Assistance Publique, Hopitaux de Paris), Paris, France; Paris 7 University, Paris, France. Department of Oncology and Haematology, Kantonsspital Graubuenden, Chur, Switzerland.
Journal:Ann Oncol. 2021 Feb;32(2):142-156. doi: 10.1016/j.annonc.2020.11.002. Epub 2020 Nov 19.

3:Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.
Authors:Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Komrokji R, Steensma D, Balleari E, Götze KS, Kotsianidis I, Guerci-Bresler A, Stamatoullas A, Sanz GF, Germing U, Fenaux P
Institution:Centre hospitalo-universitaire (CHU) Grenoble Alpes, Service d'hematologie, Universite Grenoble Alpes, INSERM U1209, Institute for Advanced Biosciences, UMR CNRS 5309, CS 10217, 38043, GRENOBLE Cedex 09, France. Electronic address: spark@chu-grenoble.fr. Hopital Saint Louis, APHP, and Universite de Paris, France.
Journal:Leuk Res. 2020 Dec;99:106472. doi: 10.1016/j.leukres.2020.106472. Epub 2020 Nov 5.

4:The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
Authors:Liu B, Guo Y, Deng L, Qiao Y, Jian J
Institution:The First Clinical Medical College, Lanzhou University, Lanzhou, People's Republic of China.
Journal:Hematology. 2020 Dec;25(1):414-423. doi: 10.1080/16078454.2020.1843752.

5:Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.
Authors:Hebeda K, Boudova L, Beham-Schmid C, Orazi A, Kvasnicka HM, Gianelli U, Tzankov A
Institution:Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands. Institute of Medical Genetics and Pathology, University Hospital of Basel, Schoenbeinstrasse 40, CH-4031, Basel, Switzerland. Alexandar.Tzankov@usb.ch.
Journal:Ann Hematol. 2021 Jan;100(1):117-133. doi: 10.1007/s00277-020-04307-9. Epub 2020 Oct 31.

6:Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Authors:Yuan XL, Tan YM, Shi JM, Zhao YM, Yu J, Lai XY, Yang LX, Huang H, Luo Y
Institution:Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China. luoyijr@zju.edu.cn.
Journal:Ann Hematol. 2021 Feb;100(2):517-527. doi: 10.1007/s00277-020-04326-6. Epub 2020 Oct 31.

7:Myelodysplastic Syndromes.
Authors:Cazzola M
Institution:From Fondazione IRCCS Policlinico San Matteo and the University of Pavia, Pavia, Italy.
Journal:N Engl J Med. 2020 Oct 1;383(14):1358-1374. doi: 10.1056/NEJMra1904794.

8:Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes.
Authors:Jain T, DeZern AE
Institution:Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland. Electronic address: Adezern1@jhmi.edu.
Journal:Biol Blood Marrow Transplant. 2020 Nov;26(11):e263-e264. doi: 10.1016/j.bbmt.2020.09.012. Epub 2020 Sep 19.

9:No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
Authors:Toriyama E, Hata T, Yokota KI, Chiwata M, Kamijo R, Hashimoto M, Taguchi M, Horai M, Matsuo M, Matsuo E, Takasaki Y, Kawaguchi Y, Itonaga H, Sato S, Ando K, Sawayama Y, Taguchi J, Imaizumi Y, Tsushima H, Jo T, Yoshida S, Moriuchi Y, Miyazaki Y
Institution:Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Journal:Cancer Sci. 2020 Dec;111(12):4490-4499. doi: 10.1111/cas.14653. Epub 2020 Oct 23.

10:Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases.
Authors:Zhang K, Lian Y, Guan X, Hu Q, Lei L, Tao L, He D, Lin J, Hou Z, Ren L, Liu X, Ren Q, Pan L, Fei X, Xiong M, Wen S, Cao J
Institution:Department of Hematology, Chengdu First People's Hospital, Chengdu, 610041, Sichuan Province, China. zhangkaijipzh@126.com.
Journal:Ann Hematol. 2020 Nov;99(11):2539-2546. doi: 10.1007/s00277-020-04268-z. Epub 2020 Sep 17.

11:Severe thrombocytopenia as a predictor of survival and response to hypomethylating agents in myelodysplastic syndromes: A Latin-American cohort of 212 patients.
Authors:Lazzarino C, Arbelbide J, Schuster S, Crisp R, González J, Tavares R, Perusini MA, Di Stefano M, Pintos N, Espinosa D, Pimentel M, Rosenhain M, Serrano JC, Enrico A, Iastrebner M, Belli CB
Institution:Hospital Interzonal General de Agudos Dr. Diego Paroissien, Isidro Casanova, Argentina. Instituto de Medicina Experimental (IMEX-CONICET) / Academia Nacional de Medicina, Ciudad Autonoma de Buenos Aires, Argentina.
Journal:Am J Hematol. 2020 Dec;95(12):E323-E326. doi: 10.1002/ajh.25987. Epub 2020 Oct 1.

12:Outcome of allogeneic hematopoietic stem cell transplantation for hypoplastic myelodysplastic syndrome.
Authors:Zhou M, Wu L, Zhang Y, Mo W, Li Y, Chen X, Wang C, Pan S, Xu S, Zhou W, Deng T, Wang S
Institution:Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People's Republic of China. eywangshq@scut.edu.cn.
Journal:Int J Hematol. 2020 Dec;112(6):825-834. doi: 10.1007/s12185-020-02969-9. Epub 2020 Aug 16.

13:Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium.
Authors:Nakano TA, Lau BW, Dickerson KE, Wlodarski M, Pollard J, Shimamura A, Hofmann I, Sasa G, Elghetany T, Cada M, Dror Y, Ding H, Allen SW, Hanna R, Campbell K, Olson TS
Institution:University of Colorado School of Medicine, Aurora, Colorado. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Journal:Pediatr Blood Cancer. 2020 Oct;67(10):e28652. doi: 10.1002/pbc.28652. Epub 2020 Aug 11.

14:A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Authors:Saygin C, Larkin K, Blachly JS, Orwick S, Ngankeu A, Gregory CT, Phelps MA, Mani S, Walker A, Garzon R, Vasu S, Walsh KJ, Bhatnagar B, Klisovic RB, Grever MR, Marcucci G, Byrd JC, Blum W, Mims AS
Institution:Department of Internal Medicine, The Ohio State University, Columbus, Ohio. Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Journal:Am J Hematol. 2020 Dec;95(12):1457-1465. doi: 10.1002/ajh.25958. Epub 2020 Sep 19.

15:Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Authors:Garcia-Manero G, Chien KS, Montalban-Bravo G
Institution:Section of MDS, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Journal:Am J Hematol. 2020 Nov;95(11):1399-1420. doi: 10.1002/ajh.25950.

16:Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia.
Authors:Brownstein CG, Daguenet E, Guyotat D, Millet GY
Institution:Univ Lyon, UJM-Saint-Etienne, Inter-University Laboratory of Human Movement Biology, EA 7424, F-42023, Saint-Etienne, France. Electronic address: callum.brownstein@univ-st-etienne.fr. Univ Lyon, UJM-Saint-Etienne, Inter-University Laboratory of Human Movement Biology, EA 7424, F-42023, Saint-Etienne, France; Institut Universitaire de France (IUF), France.
Journal:Crit Rev Oncol Hematol. 2020 Oct;154:103067. doi: 10.1016/j.critrevonc.2020.103067. Epub 2020 Jul 27.

17:Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Authors:Winters AC, Maloney KW, Treece AL, Gore L, Franklin AK
Institution:Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, Colorado.
Journal:Pediatr Blood Cancer. 2020 Oct;67(10):e28398. doi: 10.1002/pbc.28398. Epub 2020 Jul 31.

18:Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.
Authors:Del Galy AS, Marouf A, Raffoux E, Robin M, Michonneau D, Sébert M, Sicre de Fontebrune F, Xhaard A, Lengline E, Itzykson R, Frieri C, Dombret H, Fenaux P, Peffault de Latour R, Adès L, Socié G
Institution:Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France. gerard.socie@aphp.fr.
Journal:Leukemia. 2021 Jan;35(1):225-228. doi: 10.1038/s41375-020-1004-9. Epub 2020 Jul 30.

19:Eat and be healthy: nutritional status in myelodysplastic syndromes.
Authors:Kishtagari A, Sekeres MA
Institution:Department of Translational Hematology and Oncology Research, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Journal:Leuk Lymphoma. 2020 Dec;61(12):2788-2789. doi: 10.1080/10428194.2020.1797015. Epub 2020 Jul 25.

20:Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions.
Authors:Tanasijevic AM, Revette A, Klepin HD, Zeidan A, Townsley D, DiNardo CD, Sebert M, DeZern AE, Stone RM, Magnavita ES, Chen R, Sekeres MA, Abel GA
Institution:Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Journal:Leuk Lymphoma. 2020 Dec;61(12):2900-2904. doi: 10.1080/10428194.2020.1791854. Epub 2020 Jul 15.

21:Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?
Authors:Robin M, Fenaux P
Institution:Service d'hematologie-greffe, hopital Saint-Louis, Assistance Publique Hopitaux de Paris (APHP) and Universite de Paris, Paris, France. marie.robin@aphp.fr. Service d'hematologie-senior, hopital Saint-Louis, Assistance Publique Hopitaux de Paris (APHP) and Universite de Paris, Paris, France.
Journal:Leukemia. 2020 Oct;34(10):2552-2560. doi: 10.1038/s41375-020-0967-x. Epub 2020 Jul 13.

22:Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia.
Authors:Martins F, Kruszewski M, Scarpelli I, Schoumans J, Spertini O, Lübbert M, Blum S
Institution:Centre Hospitalier Universitaire Vaudois (CHUV), Hematology Service and Central laboratory, Oncology department, Rue du Bugnon 46, Lausanne, CH-1011, Switzerland. filipe.martins@gepfl.ch. Service and Central Laboratory of Hematology, Department of Oncology and Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Rue du Bugnon 46, Lausanne, CH-1011, Switzerland. sabine.blum@chuv.ch.
Journal:Ann Hematol. 2021 Jan;100(1):63-78. doi: 10.1007/s00277-020-04114-2. Epub 2020 Jun 16.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: July 6, 2021
217 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS63903402

Coupon Expires: September 4, 2021



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2021 Medifocus, Inc. All rights reserved.